Real‐World Assessment of Psychotropic and Antiepileptic Drug Use During Pregnancy in Belgium: Trends, Predictors, and Comparative Risk of Congenital Anomalies (2010–2016)
Authors:
- 7 October 2024
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 33 (10) , e70021
Abstract
Purpose: To analyze the prescription patterns and sociodemographic factors associated with the use of antipsychotic, antidepressant, and antiepileptic drugs during pregnancy in Belgium, and to investigate their potential association with congenital anomalies.Methods: Using a nationwide linked database, we identified antidepressants, antipsychotics, and antiepileptics via the Anatomical Therapeutic and Chemical Classification (ATC) codes. For each medication group, we calculated the overall prevalence and prevalence for the three most used medications at the fifth ATC level. Sociodemographic factors influencing medication use during pregnancy were analyzed, and potential associations with congenital anomalies were investigated through logistic regression models based on generalized estimating equations.Results: Overall, 828 016 live births pregnancies associated with 611 094 mothers were identified. We found that the use of antidepressants, antipsychotics, and antiepileptics was decreasing with the arrival of pregnancy. Mothers with a less favorable sociodemographic status were more likely to be exposed to these medications. Antiepileptics used in the first trimester were associated with an increased risk of congenital anomalies (aOR = 1.65, 95% CI 1.11–2.45) compared with unexposed women. The three most used antiepileptics were lamotrigine, valproate, and levetiracetam, among them, we found an association with congenital anomalies only for valproate (aOR = 3.92, 95% CI 2.30–6.67).Conclusions: Psychotropic and antiepileptic drug use decreased during pregnancy. Pregnant women with a less favorable sociodemographic status were more likely to be exposed to psychotropics and antiepileptics during pregnancy. The elevated risk of congenital anomalies associated with antiepileptics use, particularly valproate, underscores the need for targeted interventions and increased awareness to improve maternal and fetal health outcomes.Keywords
This publication has 43 references indexed in Scilit:
- Belgian medication exposure during pregnancy (BeMeP), a new nationwide linked database: Linkage methods and prevalence of medication usePharmacoepidemiology and Drug Safety, 2023
- Prescription of antiepileptic medicines including valproate in pregnant women: A study in three European countriesPharmacoepidemiology and Drug Safety, 2019
- Trends in prescription drug use during pregnancy and postpartum in Norway, 2005 to 2015Pharmacoepidemiology and Drug Safety, 2018
- Maternal Use of Antiepileptic Agents During Pregnancy and Major Congenital Malformations in ChildrenJAMA, 2017
- Antidepressant Use During Pregnancy and the Risk of Autism Spectrum Disorder in ChildrenJAMA Pediatrics, 2016
- Antiepileptic drug prescribing before, during and after pregnancy: a study in seven European regionsPharmacoepidemiology and Drug Safety, 2015
- Unemployment among patients with newly diagnosed first-episode psychosis: prevalence and clinical correlates in a US sampleSocial Psychiatry and Psychiatric Epidemiology, 2011
- A Meta-analysis of Depression During Pregnancy and the Risk of Preterm Birth, Low Birth Weight, and Intrauterine Growth RestrictionArchives of General Psychiatry, 2010
- Perception of risk regarding the use of medications and other exposures during pregnancyEuropean Journal of Clinical Pharmacology, 2009
- 12-Month Prevalence of Depression Among Single and Married Mothers in the 1994 National Population Health SurveyCanadian Journal of Public Health, 1999